Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Positive Results - Reduce Amyloid β in Alzheimer's DiseasePRNewsWire • 01/04/22
Hoth Therapeutics Announces Submission of Orphan Drug Designation Request for HT-KIT to Treat MastocytosisPRNewsWire • 12/21/21
Hoth Therapeutics' Enrollment and Dosing in Second Cohort in Phase 1b Human Trial for Atopic Dermatitis Under WayPRNewsWire • 11/30/21
Hoth Therapeutics Announces a Sponsored Research Agreement to Further Develop Novel mRNA Cancer Therapeutic HT-KITPRNewsWire • 11/16/21
Hoth Therapeutics Inks API and Drug Product Contracts with WuXi STA to Advance Manufacturing of HT-KIT Cancer TherapeuticPRNewsWire • 11/08/21
Hoth Therapeutics Receives Approval to Commence Cohort 2 in Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis in HumansBenzinga • 10/12/21
Hoth Therapeutics Receives Approval to Commence Cohort 2 in Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis PatientsPRNewsWire • 10/12/21
Hoth Therapeutics Submits to Ethics Committee for Approval to Initiate Patient Cohort 2 in BioLexa Clinical TrialPRNewsWire • 09/21/21
Hoth Therapeutics Announces Positive Phase 1b Results for Completed First Cohort of Patient Trial of BioLexaPRNewsWire • 09/08/21
Hoth Therapeutics' mRNA 'Frameshifting' Therapy HT-KIT for Mast Cell Cancers Reduces Size, Spread - Research Published in Molecular TherapyPRNewsWire • 08/11/21
Hoth Therapeutics Announces Positive Confirmatory Results from In Vivo Model of HT-003 Assets as Potential Treatment Against AcnePRNewsWire • 07/13/21